BMJ Open

Systematic review of copper intrauterine contraception continuation in young nulliparous women based on intrauterine device type

Hannat Akintomide ,[1] Alison James ,[2] Malcolm Moffat ,[3] Pam Barnes,[1] Judith Rankin[3]

To cite: Akintomide H, James A, Moffat M, *et al*. Systematic review of copper intrauterine contraception continuation in young nulliparous women based on intrauterine device type. *BMJ Open* 2022;**12**:e060606. doi:10.1136/bmjopen-2021-060606

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-060606).

Received 28 December 2021
Accepted 09 August 2022

[1]Sexual Health Services, New Croft Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
[2]School of Nursing and Midwifery, Faculty of Health, University of Plymouth, Plymouth, UK
[3]Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

Correspondence to
Dr Hannat Akintomide;
h.akintomide@nhs.net

ABSTRACT

Objectives No copper intrauterine device (IUD) type is known to better suit young nulliparous women who tend to experience higher rates of IUD discontinuation compared with their older parous counterparts. A systematic review to determine which IUDs have higher continuation rates in young nulliparous women was undertaken.

Design Systematic review and meta-analyses of available evidence based on IUD type.

Data sources AMED, BNI, CINAHL, DARE, EMBASE, EMCARE, HMIC, MEDLINE, PsycINFO, PubMed, TRIP, and the Cochrane Library electronic databases were searched from inception to 11 May 2022; as well as the Bandolier, Medicines and Healthcare products Regulatory Agency, Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists, Department of Health, National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines, WHO and Google Scholar websites.

Eligibility criteria All studies on IUDs currently available in the UK or comparable (same design and size) to those available in the UK, involving nulliparous women of any age including those aged under 30.

Data extraction and synthesis Independently extracted data were assessed as low risk of bias using the Mixed Methods Appraisal Tool. Random effects meta-analyses of proportions were performed where data, including subgroups, were amenable to quantitative synthesis. Heterogeneity was reported using tau^2 and I^2 statistics, and sensitivity analyses were also performed.

Results Nineteen studies involving 13 045 nulliparous women were included but the heterogeneity of participant ages, parity and IUD types made quantitative synthesis of outcome data in totality inappropriate. The highest continuation rate obtained was 91.02% (95% CI 88.01% to 93.64%) for the smaller TCu 380A at 12 months post insertion.

Conclusions Evidence for IUD use in young nulliparous women based on IUD type remains limited. Smaller sized IUD types appear better suited to this group of IUD users, however, more research is needed.

PROSPERO registration number CRD42019120969.

STRENGTHS AND LIMITATIONS OF THE STUDY

⇒ The first reported systematic review exploring intrauterine device (IUD) types in young nulliparous women.
⇒ A wide range of data sources, unrestricted to randomised controlled trials, was reviewed —an approach more representative of the real world.
⇒ Articles for inclusion were limited to publications in the English language.
⇒ Some data were obtained by calculation and measurements of graphs or figures where these data were not numerically specified in reports.
⇒ Most studies did not differentiate between nulligravid and nulliparous participants.

INTRODUCTION

The highest rates of unintended pregnancy and terminations of pregnancy, which contribute to poor sexual health, are in women aged 20–24 followed by those aged 25–29.[1] Increasing uptake of long-acting reversible contraceptives (LARCs), such as copper intrauterine contraception, in these women is yet to yield a proportional reduction in pregnancy terminations. This is attributable to their higher LARC discontinuation rates.[2]

Copper intrauterine contraception is the LARC with the greatest number of brands, with 21 copper intrauterine devices (IUDs) available in the UK.[3] IUDs are of various shapes, sizes, total copper surface area and copper distribution on the IUD frame. They have changed little over the last 40 years. No IUD type has been shown to be associated with better outcomes regarding unwanted effects that lead to early IUD discontinuation. This early IUD discontinuation excludes discontinuation due to IUD user choice alone or the wish to conceive. IUD continuation rates tend to be surrogate for IUD satisfaction and/or acceptability. Studies have shown IUD discontinuation rates to be higher in adolescents and women in their 20s compared with their

older counterparts, as well as in nulliparous compared with parous women.[4–8]

Previous systematic reviews and guidance suggest that IUD size and shape may be a factor in discontinuation, and have recommended future research investigate which IUD types are associated with less pain, bleeding and discontinuation.[7 9–11] The identification and use of IUDs with higher continuation rates and fewer unwanted effects could improve outcomes including IUD satisfaction for young nulliparous women. A systematic review and meta-analysis were therefore undertaken to investigate continuation rates and reasons for discontinuation of IUDs, currently available, or comparable to those currently in use in the UK, based on IUD type involving women aged under 30.

OBJECTIVES

This study aimed to determine which currently available IUDs have higher continuation rates, in nulliparous women aged under 30, by systematically reviewing published studies. Discontinuation rates and reasons for discontinuation were secondary outcomes.

METHODS

An appraisal of previous systematic reviews, including publications by the Cochrane Collaboration Fertility Regulation Group, Faculty of Sexual and Reproductive Healthcare (FSRH) and National Institute for Health and Care Excellence (NICE), was performed. A search strategy was developed in conjunction with an Electronic Services Librarian. These informed the design of this systematic review and its protocol.

This study is reported as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (see online supplemental material 1). Its protocol was registered on the International Prospective Register of Systematic Reviews database (see online supplemental material 2).[12] The protocol included other studies besides randomised controlled trials (RCTs) reporting on IUD continuation, in case the RCTs determined eligible for inclusion in the systematic review were too few to address the review question.

Selection criteria

Inclusion criteria

Inclusion criteria are as follows: articles published in English, on studies in women who are nulliparous and aged under 30, that involved IUDs available or of the same design and size, to those available in the UK.

Exclusion criteria

Exclusion criteria are as follows: articles not published in English, studies solely in parous women aged 30 or over 30, that involved IUDs not available, or not of the same design and size to those available in the UK.

Where studies on IUDs currently available in the UK were lacking, studies with IUDs comparable in shape, size, total copper surface area or distribution on the IUD frame to those currently available in the UK were included. Where studies involving only nulliparous women aged under 30 were lacking, studies with nulliparous women of all ages (incorporating those aged under 30) were also included in the review.

Search strategy

Nine electronic databases—the Allied and Complementary Medicine (AMED), British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Excerpta Medica Database (EMBASE), Nursing and Allied Health Professionals Database (EMCARE), Health Management Information Consortium (HMIC), General Medical Database (MEDLINE), Psychology and Allied Fields (PsycINFO) and PubMed—were searched. The search terms were (copper intrauterine).ti,ab OR (copper intrauterine device).ti,ab OR (copper coil).ti,ab OR (copper IUD).ti,ab OR (copper T).ti,ab from database inception to 7 February 2021 (updated to 11 May 2022). The following additional sources were searched using the term 'copper intrauterine': the Cochrane Library, Database of Abstracts and Reviews of Effects (DARE), Turning Research into Practice (TRIP) database, National Electronic Library of Health (merged with MEDLINE), Bandolier, Medicines and Healthcare products Regulatory Agency, FSRH, Royal College of Obstetricians and Gynaecologists, Department of Health, NICE, Scottish Intercollegiate Guidelines and WHO websites. A Google Scholar search was also undertaken using the term 'copper intrauterine device young nulliparous'. The full search strategy is provided as a supplementary file (online supplemental material 3).

Relevant articles published in English were identified by two authors and these were exported into an Endnote library on completion of all the searches. Following deduplication, the relevant articles obtained from the searches were exported to Rayyan, a web app for systematic reviews (rayyan.ai). In Rayyan, further deduplication yielded unique entries of which abstracts, and then full texts, were screened independently by two authors to assess eligibility for inclusion in the systematic review based on the inclusion/exclusion criteria. Additional citation screening of reference lists of both included and excluded studies was performed. Screening was initially done in batches of 20, then later increased to 50. Agreements were obtained between the first two authors and did not require a third review. Selected articles were RCTs and observational studies published in English, involving IUDs available or comparable to those in the UK, and involving nulliparous women aged under 30.

Quality assessment and data summary

All articles selected for inclusion in the systematic review underwent a quality assessment using the Mixed Methods Appraisal Tool (MMAT), v.2018.[13] The MMAT risk of bias

tool was chosen because it was applicable to all the study types selected for inclusion. The highest total MMAT score conforming with best quality was seven, while the lowest possible score equating with poorest quality was zero. Included articles were initially quality assessed by the two authors separately and then agreement was reached.

Data extracted from articles included IUD type, study location(s) and year of publication, age of women, gravidity/parity of women, IUD continuation and discontinuation rates and reasons for IUD discontinuation. Where a rate was not specified but could be reliably calculated, this was done to one decimal place. If a continuation rate was not specified, this was obtained by subtracting the discontinuation rate from 100, or adding all stated rates for reasons for discontinuation (where these were mutually exclusive) and subtracting from 100, if the report suggested such a calculation to be valid. If a discontinuation rate was not specified, this was obtained by subtracting a stated continuation rate from 100, or by adding all stated rates for reasons for discontinuation (where these were mutually exclusive), if the report suggested such a calculation was valid. Gross rates (obtained after excluding participants lost to follow-up or removals to conceive) were used, except where only net cumulative rates were reported. Measurements were performed to obtain data from published graphs or figures where rates had been reported in this format but not numerically specified.

An Excel data collection form was developed, piloted with three articles selected for inclusion by one author, then revised and amended by the second author before proceeding to data extraction. Data from the 19 selected articles included in the review were extracted by one author into the Excel spreadsheet and checked by the second author.

Data analysis

Where available, data were amenable to quantitative synthesis, random effects meta-analyses of proportions were performed using the metaprop suite of commands on STATA 16. Variances were stabilised using the Freeman-Tukey double arcsine transformation. This approach provides better approximation and leads to results between 0% and 100% when synthesising proportions from small samples and multiple studies in meta-analyses.[14] Where possible, subgroup analysis was performed to examine differences between nulliparous women aged ≤30 years and nulliparous women of any age. Statistical heterogeneity was reported using I^2 and tau^2 statistics, since random effects meta-analyses were being performed. The I^2 value describes the percentage of the variability in effect estimates that is due to statistical heterogeneity (reflecting methodological diversity among the included studies) as opposed to chance. Conventionally, while an I^2 value <40% may not be significant, a value >50% may represent substantial heterogeneity and a value >75% may indicate considerable heterogeneity.[15] The tau^2 statistic measure of 'between-study variance', unlike the I^2 statistic, is not affected by size of included studies in a meta-analysis and hence may be considered more appropriate for estimating heterogeneity.[16] The effect of removing individual studies on the overall effect size (ES) was explored in sensitivity analyses (online supplemental material 4). Publication bias was examined by producing Doi plots and generating LFK index values, being considered a more appropriate measure of publication bias than funnel plots/Egger's test when performing meta-analyses of proportions.[17]

Patient and public involvement

The FSRH is the UK organisation committed to meeting the highest SRH standards, ensuring improvements in population SRH and supporting SRH professionals. The FSRH's Contraceptive Priority Setting Partnership in liaison with the James Lind Alliance yielded over 700 responses from patients, practitioners and the public that identified: 'Which interventions increase uptake and continuation of effective contraception including long-acting methods…?' as the top SRH research priority.[18] This influenced the research aims. IUD users attending a

Table 1 Characteristics of IUDs in the included studies

IUD brand/name	Copper (mm^2)	Shape/design	Width (mm)	Arms' flexibility
Currently available in the UK				
Cu T380A/TCu 380A/TT380 Slimline	380	T with arm bands	>30	No
TCu 380A Nul/Mini TT380 slimline	380	T with arm bands	23.2	No
Multiload Cu 375	375	Ω	16–20.5	Yes, flex down
Nova T380	380	T without arm bands	>30	Yes, flex up
Comparable to those available in the UK				
Nova T200	200	T without arm bands	≥30	Yes, flex up
TCu 300	300	T without arm bands	>30	No
Cu T200/TCu 200	200	T without arm bands	>30	No
TCu 220C	220	T without arm bands	>30	No

IUD, intrauterine device.

Table 2 Characteristics of the included studies

Study/authors	Year	Country	Study design	Study objectives	IUDs in study	Quality (MMAT score)
Abraham *et al*[19]	2015	USA	Prospective cohort	Relationship among young age, nulliparity and continuation of long-acting reversible contraceptives	Copper T380A	Good (7)
Akintomide *et al*[30]	2019	UK	Retrospective records review	Discontinuation rates and reasons for discontinuation at 1 year of the small-sized Mini TT380 Slimline IUD compared with the standard-sized TT380 Slimline	Mini TT380 slimline TT380 slimline	Good (6)
Allonen *et al*[31]	1980	Denmark, Finland Sweden	RCT—double blind	Continuation rates and reasons for discontinuation at 2 years of the Nova T200 and Copper T200	Nova T200 Copper T200	Good (6)
Elkhateeb *et al*[32]	2020	Egypt	Prospective cohort	Acceptability of IUD use in nulliparous women by both women and healthcare providers	Copper T380A	Good (7)
Fugere[33]	1990	Canada	Prospective cohort	Clinical performance of the Nova T200 IUD over 5 years	Nova T200	Good (7)
Hall and Kutler[34]	2016	USA	Prospective cohort	Experience and satisfaction of nulliparous intrauterine contraception users at 1, 6, 12 and 18 months	Copper T380A	Good (7)
Kaislasuo *et al*[35]	2015	Finland	Prospective cohort	Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception	Nova T380	Good (7)
Larsen *et al*[36]	1981	Denmark	RCT—patient blind	Comparison of clinical performances of Progestasert and Copper T200 at 12 months	Copper T200	Good (5)
Lewit[37]	1973	USA	Prospective cohort	Two years' experience of the Copper T200	Copper T200	Good (7)
Liedholm and Sjöberg [38]	1974	Sweden	Prospective cohort	Two years' experience with the Copper T200 and comparison between nulliparous and parous women	Copper T200	Good (7)
Luukkainen *et al*[39]	1979	Denmark, Finland Sweden	RCT—double blind	Experience and clinical performance of the Nova T200 and Copper T200 at 12 months	Nova T200 Copper T200	Good (6)
Luukkainen *et al*[40]	1987	Denmark, Finland, Hungary, Norway, Sweden	RCT—no blinding	Use-effectiveness and clinical performance of levonorgestrel-releasing and copper-releasing intrauterine devices at 12 months	Nova T200	Good (6)
Mishell *et al*[41]	1973	USA	Prospective cohort	Continuation and clinical performance of TCu 200 in nulliparous women	Copper T200	Good (7)
Nygren *et al*[42]	1981	Denmark, Finland Sweden	RCT—double blind	Continuation rates and reasons for discontinuation at 3 years of the Nova T200 and Copper T200	Nova T200 Copper T200	Good (7)

Continued

Table 2 Continued

Study/authors	Year	Country	Study design	Study objectives	IUDs in study	Quality (MMAT score)
Ostergard and Gunning[43]	1979	USA	RCT—blinding not stated	Continuation and clinical performances of Copper T200 and Dalkon Shield in nulligravid women at 12 months	Copper T200	Good (5)
Otero-Flores *et al*[44]	2003	Mexico	RCT—single (patient) blind	Comparison of clinical performance of three different IUDs in nulliparous women	Copper T380A Copper T380A Nul Multiload 375 sl	Good (6)
Roy *et al*[45]	1974	USA	Prospective cohort	Experience with three different IUD models in nulliparous women at 1 year	Copper T380A Copper T300 Copper T200	Good (7)
Sivin and Stern[46]	1979	USA	RCT—double blind	Experience of three different IUDs in nulliparous and parous women	Copper T380A Copper T220C Copper T200	Good (5)
Timonen *et al*[47]	1974	Finland	Prospective, single (patient) blind	Use-effectiveness of Copper T300 at 1 year	Copper T300	Good (7)

IUD, intrauterine device; MMAT, Mixed Methods Appraisal Tool; RCT, randomised controlled trial.

sexual health clinic over a 4-week period were consulted about improving access to and use of intrauterine contraception. Their suggestions, which included studying women's experiences with IUDs, were used in developing the research question, aim and study design. The Consumer Panel of the North East Research Design Service was also consulted and the proposed research presented to them. The research plan was modified in line with their feedback.



Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.

RESULTS

Only one study, a prospective (non-RCT) cohort study, provided information on an IUD available in the UK, solely involving nulliparous users aged under 30.[19] This was inadequate to address the review question. As per the systematic review protocol, other studies on IUDs currently available in the UK or IUDs comparable to those available in the UK (table 1) involving nulliparous women of all ages (so not limited to those aged under 30) were also screened. An IUD was considered comparable if at least two out of its four characteristics (copper surface area, shape/design, width and arms flexibility) equated with IUDs currently used in the UK. So, for example, the Nova T200 was comparable because it has the same shape/design as a Nova T380, the same width as a Nova T380/Cu T380A/TCu 380A and TT380 slimline, and the same flexible arms as a Nova T380 (table 1).

Thirty records were obtained and their full texts assessed where possible. Eleven records were excluded, either for lack of usable outcome data (n=8[5 20–26]) or because their full texts were unobtainable (n=3[27–29]) (see online supplemental material 5). A total of 19 studies on IUDs available or comparable to those available in the UK, involving 13 045 nulliparous women, were included in the systematic review (table 2).[19 30–47] Figure 1 depicts a PRISMA flow diagram detailing the search and selection process.[48]

All included studies were generally of good quality (mean 6.42 [5-7]; see online supplemental material 6 for quality and risk of bias assessments). The lowest MMAT score of five obtained was awarded to three RCTs

Table 3 Summary of findings

Study	IUD types (N*)	Age at insertion (years)	Study period	Continuation rates % (n)	Discontinuation rates % (n)	Removal for bleeding/pain % (n)	Expulsion % (n)	Pregnancy % (n)
Studies of IUD types currently available in the UK only involving nulliparous women aged ≤30								
RCT								
Otero-Flores *et al* [44]*†	TCu 380A (375) TCu 380A Nul (367) ML Cu 375 sl (374)	23.2±6.8 22.4±6.6 22.6±6.4	12 months	30.7 (115) 91.3 (335) 89.0 (333)	69.3 (260) 8.7 (32) 11.0 (41)	61.6 (231) 3.81 (14) 6.68 (25)	3.47 (13) 1.91 (7) 1.87 (7)	1.07 (4) 0.54 (2) 0.00 (0)
Non-RCT								
Abraham *et al*[19]	Cu T380A (201) Cu T380A (44) Cu T380A (201) Cu T380A (44)	20–25 <20 20–25 <20	12 months 24 months	82 [95% CI 76-87] 79 [95% CI 64-89] 73 [95% CI 66-79] 64 [95% CI 48-77]	ns ns	ns ns	ns ns	ns ns
Hall and Kutler[34]	Cu T 380A (21)	18–30	12 months	73.7 (14)	26.3 (5)	10.5 (2)	10.5 (2)	5.26 (1)
Studies of IUD types currently available in the UK involving nulliparous women of all ages								
RCTs								
Sivin and Stern[46]‡§	TCu 380A (2254) TCu 220C (1301) TCu 200 (4215)	<20–35+ <20–35+ <20–35+	2 years	55.7 57.8 54.2	44.3 42.2 45.8	21.9 19.5 16.8	7.8 9.8 9.8	0.8 1.6 5.1
Non-RCTs								
Akintomide *et al*[30]	TT380 Slimline (27) Mini TT380 Slimline (53)	15–37 16–37	1 year	66.7 (18) 86.8 (46)	33.3 (9) 13.2 (7)	ns ns	3.7 (1) 3.77 (2)	0 (0) 0 (0)
Elkhateeb *et al*[32]	TCu 380A (90)	16–>30	6 months	94.4 (85)	5.6 (5)	ns	0 (0)	ns
Kaislasuo *et al*[35]†	Nova T380 (42)	18–43	1 year	83.3 (35)	16.7 (7)	ns	4.76 (2)	ns
Roy *et al*[45]	TCu 380A (785) TCu 300 (347) TCu 200 (472)	<14–>33 15–>33 <14–>33	12 months	81.9 80.7 74.2	18.1 19.3 25.8	9.1 9.2 10.7	3.8 6.1 5.4	0.2 0.6 1.7
Studies of IUD types comparable to those available in the UK involving nulliparous women of all ages								
RCTs								
Luukkainen *et al*[39]§¶	Nova T200 (ns) Cu T200 (ns)	≤19–≥35 ≤19–≥35	12 months	ns ns	ns ns	15.3 23.4	6 10.8	0.53 2.3
Allonen *et al*[31]§¶	Nova T200 (ns) Cu T200 (ns)	≤19 -≥35 ≤19 -≥35	24 months	ns ns	ns ns	23.5 24	6.5 14	1.14 5.28
Nygren *et al*[42]§	Nova T200 (ns) Cu T200 (ns)	<20 ->35	36 months	36.9 31.0	ns ns	28.3 (74) 28.2 (68)	10.3 (27) 10.7 (26)	1.5 (4) 6.5 (15)
Larsen *et al*[36]§	Cu T200 (99)	15–44	12 months	73	27**	16	5	1
Luukkainen *et al*[40]	Nova T200 (77)	17–40	12 months	73.1	26.9**	10.4	9.2	0
Ostergard and Gunning[43]	TCu 200 (117) TCu 200 (115)	18–34	6 months 12 months	88.9 (104) 73.0 (84)	11.1 (13) 27.0 (31)	6.0 (7) 12.2 (14)	3.41 (4) 6.09 (7)	0 (0) 0 (0)
Non-RCTs								
Fugere[33]	Nova T200 (54)	17–42	24 months	ns	ns	17.2	1.9	0

Continued

Table 3 Continued

Study	IUD types (N*)	Age at insertion (years)	Study period	Continuation rates % (n)	Discontinuation rates % (n)	Removal for bleeding/pain % (n)	Expulsion % (n)	Pregnancy % (n)
Lewit[37]	TCu-200 (2099)	15–49	1 year	73.3	26.7	9.4	10.7	1.3
	Nulligravid subgroup: TCu-200 (1585)†	15–49	1 year	75.9	24.1	9.6	8.7	0.8
	Age subgroups:							
	TCu-200 (1130)	15–19	1 year	67.3	32.7	7	15	2.3
	TCu-200 (2468)	20–24	1 year	73.8	26.2	8.3	8.5	2.8
	TCu-200 (1513)	25–29	1 year	77.6	22.4	5.8	8.7	1.5
	TCu-200 (683)	30–34	1 year	81.7	18.3	7.9	6	0.4
	TCu-200 (449)	35–49	1 year	85.2	14.8	6.8	3.1	0.3
Liedholm and Sjöberg[38]	T-Cu 200 (208)	14–40	12 months	70.2	29.8	18.1	0.5	2.9 (6)
			24 months	60.3	39.7	28	0.5	2.9 (6)
Mishell *et al*[41]§	TCu 200 (471)	14–33	3 months	92.6	7.4	2.8	2.6	0.2
			6 months	84.5	15.5	5.8	4.7	0.4
			12 months	74.2	25.8	10.7	5.4	1.7
Timonen *et al*[47]	T Cu-300 (138)	<25–40+	12 months	84.7	15.3	7.2	1.6	1.6

*Sample size or participants excluding those lost to follow-up or removals to plan pregnancy.
†Nulligravid women only.
‡A combination of double blind studies.
§Net cumulative rates.
¶Data obtained from graphs or figures.
**Not stated; obtained by subtraction of continuation rate from 100.
IUD, intrauterine device; ns, not stated; RCT, randomised controlled trial.

Table 4 Estimated continuation rates at 12 months of IUD types from the included studies

	Continuation rates with numbers of patients (n) and statistical heterogeneity (tau^2 and I^2) values of studies included in subgroup		
IUD type	**Nulliparous women aged <30**	**Nulliparous women of any age**	**Overall effect size (all studies)**
TCu 380A*	81.60% (95% CI 76.52% to 86.21%)† (n=264; tau^2=0.0; I^2=0.0%, p=0.69)[19 34]	80.97% (95% CI 76.04% to 85.48%) (n=971; tau^2=0.005; I^2=27.6%, p=0.25)[19 30 45]	81.93% (95% CI 79.66% to 84.09%) (n=1235; tau^2=0.0; I^2=0.0%, p=0.62)[19 30 34 45]
Smaller TCu 380A‡	Not applicable—only one study group	91.02% (95% CI 88.01% to 93.64%) (n=420; tau^2=0.0; I^2=0.0%, p=0.51)[30 44]	91.02% (95% CI 88.01% to 93.64%) (n=420; tau^2=0.0; I^2=0.0%, p=0.51)[30 44]
TCu 300	Not applicable—no study	81.92% (95% CI 78.35% to 85.24%) (n=485; tau^2=0.0; I^2=17.3%, p=0.27)[45 47]	81.92% (95% CI 78.35% to 85.24%) (n=485; tau^2=0.0; I^2=17.3%, p=0.27)[45 47]
TCu 200	73.03% (95% CI 67.63% to 78.10%) (n=5111; tau^2=0.010; I^2=94.2%, p=<0.01)[37]	76.51% (95% CI 72.67% to 80.14%) (n=3277; tau^2=0.012; I^2=84.0%, p=<0.01)[37–39 41 43 45]	75.44% (95% CI 72.32% to 78.43%) (n=8388; tau^2=0.012; I^2=89.9%, p=<0.01)[37–39 41 43 45]
Nova T200	Not applicable—no study	73.21% (95% CI 70.10% to 76.22%) (n=818; tau^2=0.0; I^2=0.0%, p=0.94)[39 40]	73.21% (95% CI 70.10% to 76.22%) (n=818; tau^2=0.0; I^2=0.0%, p=0.94)[39 40]

*Excludes Otero-Flores *et al*'s study data.
†Includes women aged 30 from Hall and Kutler's study data.
‡TCu 380A Nul/Mini TT380 Slimline IUDs.
IUD, intrauterine device.



Figure 2 TCu 380A continuation rates (excluding Otero-Flores). ES, effect size.

published in 1979 and 1981 and may relate to inadequate reporting.[36 43 46] Their reports did not confirm that randomisation had been appropriately performed,[36 46] randomised groups were comparable at baseline,[43 46] nor that outcome assessors were blinded to the intervention provided.[36 43]

Although the outcome data obtained were considered homogeneous, studies' designs, participant ages and parity, and IUD types were not; making a quantitative synthesis of the outcome data in totality inappropriate. Results were therefore grouped into three to include studies involving: (1) IUD types currently available in the



Figure 3 TCu 380A continuation rates (including Otero-Flores). ES, effect size.



Figure 4 Smaller TCu 380A continuation rates. ES, effect size.

UK and only nulliparous women aged ≤30; (2) IUD types currently available in the UK and nulliparous women of all ages; (3) IUD types comparable to those available in the UK and nulliparous women of all ages (table 3). The estimated continuation rates at 12 months by IUD type, obtained from the included studies with data amenable to synthesis, is reported in table 4. Tau^2 values for heterogeneity of the included studies are provided separately (see online supplemental material 7).

Studies of IUD types currently available in the UK only involving nulliparous women aged ≤30

Three studies—Abraham *et al*[19], Hall and Kutler[34] and Otero-Flores *et al*[44]—reported on IUDs in women aged ≤30 involving the Copper T380A IUD (TCu 380A or Cu T380A).[19 34 44] The TCu 380A data obtained from Otero-Flores *et al*[44] was an outlier, with 30.7% reported as the continuation rate at 12 months.[44] This was much lower than for the other two studies with a pooled estimate of 81.60% (95% CI 76.52% to 86.21%)[19 34] (figure 2). When the Otero-Flores *et al* data were included in this TCu 380A meta-analysis, nulliparous women ≤30 years of age at 12 months had a continuation rate of 66.98% (95% CI 32.09% to 93.90%) (figure 3).

Continuation was also higher with age at 12 and 24 months when nulliparous TCu 380A IUD users aged <20 and 20–25 were compared (table 3).[19]

Studies of IUD types currently available in the UK involving nulliparous women of all ages

Five studies reporting data pertaining to seven population subgroups were amenable to meta-analysis examining the proportion of women continuing to use the TCu 380A IUD at 12 months post insertion.[19 30 34 44 45] The pooled



Figure 5 TCu 300 continuation rates. ES, effect size.



Figure 6 TCu 200 continuation rates. ES, effect size.

estimated continuation rate of the Copper T380A IUD type in nulliparous women of all ages from four studies was 81.93% (95% CI 79.66% to 84.09%).[19 30 34 45] Additionally, statistical heterogeneity was found to be low/absent but was not statistically significant (tau^2=0.0, I^2=0.0%, p=0.62). Sensitivity analysis confirmed that the overall ES was largely robust to the exclusion of individual studies (−1.01% to +0.21% change in ES; see online supplemental material 4).

The estimated TCu 380A continuation rate in nulliparous women of all ages remained good at 71.65% (95% CI 51.15% to 88.44%; tau^2=0.299, I^2=98.4%, p=<0.01) when the Otero-Flores *et al* data were included[44] (figure 3). An LFK index value of 6.77 identified major Doi plot asymmetry consistent with publication bias (see online supplemental material 8).

Individual studies showed the TCu 380A had higher discontinuation related to bleeding/pain and expulsion[34 44 46] when compared with IUDs of smaller size or those with flexible arms[30 44] (table 3).

The highest continuation rates at 12 months were reported with smaller sized IUDs—the Copper 380A Nul (TCu 380A Nul: 91.3%), Multiload Copper 375 sl (ML Cu 375 sl: 89%) and Mini TT380 slimline (86.8%) (table 3).



Figure 7 Nova T200 continuation rates. ES, effect size.

These data were obtained from only two studies whose participants were aged 15–37.[30 44] Meta-analysis of continuation rate data on the TCu 380A Nul/Mini TT380 slimline IUD type gave a weighted average of 91.02% (95% CI 88.01% to 93.64%) (figure 4). These smaller IUDs were also associated with the lowest rates of removals for bleeding/pain (3.80%–6.68%) and expulsion (1.87%–3.77%) reported in nulliparous women at 12 months (table 3).

Studies of IUD types comparable to those in the UK involving nulliparous women of all ages

Two studies reporting data pertaining to two population subgroups were amenable to meta-analysis examining the proportion of women continuing to use the Copper T300 IUD (TCu 300) at 12 months post insertion, with an overall ES of 81.92% (95% CI 78.35% to 85.24%, see figure 5).[45 47]

Seven studies reporting data pertaining to 11 population subgroups were amenable to meta-analysis examining the proportion of women continuing to use the Copper T200 IUD (TCu 200 or Cu T200) at 12 months post insertion, with a weighted average of 75.44% (95% CI 72.32% to 78.43%, see figure 6).[36–38 40 41 43 45] These studies were also amenable to meta-analysis examining the proportion of women discontinuing the TCu 200 at 12 months post insertion due to bleeding and/or pain, expulsion and pregnancy (see online supplemental material 9). For these meta-analyses, nulliparous women aged <30 years compared with nulliparous women of any age were less likely to continue to use the TCu 200 at 12 months (73.03% (95% CI 67.63% to 78.10%) vs 76.51% (95% CI 72.67% to 80.14%)), and less likely to discontinue the TCu 200 due to bleeding and/or pain (7.05% (95% CI 5.59% to 8.65%) vs 12.77% (95% CI 8.48 to 17.78%)). Nulliparous women aged <30 years compared with nulliparous women of any age were however more likely to discontinue the TCu 200 due to expulsion (10.52% (95% CI 7.17% to 14.41%) vs 4.93% (95% CI 2.93% to 7.39%)) and pregnancy (2.19% (95% CI 1.47% to 3.05%) vs 1.15% (95% CI 0.54% to 1.95%)). The overlapping confidence intervals for these two ESs suggest the difference in effect is not statistically significant, and therefore may or may not be clinically significant. Statistical heterogeneity values for overall TCu 200 continuation rates as well as discontinuation rates for bleeding/pain and expulsion were tau^2=0.012, I^2=89.9%, p=<0.01; tau^2=0.025 I^2=93.2%, p=<0.01; and tau^2=0.018, I^2=96.3%, p=<0.01 respectively (see figure 6 and online supplemental material 9). Sensitivity analyses confirmed that the overall ESs were largely robust due to the exclusion of individual studies (see online supplemental material 4). In all cases, their LFK index values identified major Doi plot asymmetry consistent with publication bias (see online supplemental material 8).

Continuation rates were seen to progressively improve with age where Lewit[37] reported rates in nulliparous TCu 200 users by age groups 15–19, 20–24, 25–29, 30–34 and 35–49[37] (table 3).

Two studies reporting data pertaining to two population subgroups were amenable to meta-analysis examining the proportion of women continuing to use the Nova T200 at 12 months post insertion, with a weighted average of 73.21% (95% CI 70.10% to 76.22%, see figure 7).[39 40]

Studies also showed that IUDs with flexible arms (Nova T, Multiload) were associated with higher continuation and lower removal rates for bleeding/pain, expulsion and pregnancy when compared with IUDs with rigid arms (Cu T or TCu)[31 39 44] (table 3).

DISCUSSION

Findings and interpretation

Evidence on IUDs currently used in nulliparous women aged under 30 is limited. These findings estimate the continuation rate for the recommended TCu 380A IUD[11] to be 81% at 12 months post insertion based on four studies involving young nulliparous women.[19 30 34 45] This was the same estimate for the TCu 300 based on two studies.[45 47] Smaller sized and flexible IUDs had higher continuation rates of 86%–91% in this group of women, based on two studies, as well as fewer removals for bleeding/pain and expulsion compared with the TCu 380A or IUDs of the same rigid design or size.[30 44] Lower continuation rates of 75% and 73% were obtained for the Cu T200 and Nova T200 based on eight studies.[36–41 43 45]

The study by Otero-Flores *et al* was the only reported RCT solely involving IUDs currently used in the UK with nulliparous women aged ≤30.[44] Over a thousand nulliparous women aged 15–30 were randomised to receive three different IUDs: TCu 380A (width 32 mm), TCu 380A Nul (width 23 mm) and ML Cu 375 sl (width≤20 mm), the latter two being primarily designed for nulliparous women. The TCu 380A overall rate of discontinuation (69.3%) and bleeding/pain as a reason for discontinuation (61.6%) were significantly higher than for TCu 380A Nul (8.7% and 3.81%) and ML Cu 375 sl (11.0% and 6.68%), as well as significantly different from rates reported by other included studies involving the TCu 380A. This could be because the TCu 380A considerably differs in size from the TCu 380A Nul and ML Cu 375 sl IUDs, and Otero-Flores *et al* also exclusively involved nulligravid participants (as opposed to nulliparous).

Sivin and Stern[46] was the only other RCT involving a TCu 380A that reported separately on nulliparous users.[46] However, their TCu 380A discontinuation and bleeding/pain rates, 44.3% and 21.9%, respectively, were obtained at 2 years and their participants were aged <20–35+ years.

The disparity in discontinuation rates reported by Otero-Flores *et al*[44] and Sivin and Stern[46] suggests that the findings by Otero-Flores *et al* may be unreliable. But it may in fact be inappropriate to directly compare other studies' TCu 380A data, including that of Sivin and Stern, to Otero-Flores *et al*'s data. Their studies' designs as well as participants' ages, gravidity/parity, environments and

reported durations of use were not the same. Otero-Flores *et al*'s participants were younger (≤30 years), exclusively nulligravid, 'highly educated' and based in a Mexico city with free access to healthcare in the millenial era, with the study being single-(patient) blinded. This contrasts with most studies involving the TCu 380A or similar IUDs where participants were more likely to be aged 30 years or older and parous with unspecified educational attainment. The Sivin and Stern study population were living and accessing healthcare (which was not stated to have been free) across the USA, in the late 1970s (over two decades earlier than the Otero-Flores *et al*'s study, and not long after the Dalkon Shield era), with the study being double-blinded. Other explanations for the disparity could be that the modern younger nulligravid cohort may be less tolerant of unwanted IUD effects, and that some contraceptive research may be less likely to acknowledge participants' reasons and wishes for early IUD discontinuation.[49]

The TCu 200 IUD was ≥33 mm in width and/or height so perhaps larger than a standard-sized TCu 380A.[50] IUD size may contribute to pain, which may explain TCu 200's lower continuation rates compared with the TCu 380A. However the TCu 300, of the same design and size as the TCu 200,[47] unexpectedly had a higher continuation rate than the TCu 200. This is because higher copper content has been associated with more bleeding which contributes to early discontinuation.[51] The TCu 300 data were limited to two studies that both had total MMAT scores of 7,[45 47] whereas the TCu 200 data had been obtained from seven studies with MMAT scores of 7,[37 38 41 45] 6[39] and 5,[43] respectively.

Strengths and limitations

This is the first systematic review to explore IUD types in younger aged nulliparous women. It has included all observational studies that provided information on IUD continuation or reasons for discontinuation in this user group. Non-restriction to RCTs may be considered a limitation, but a realist approach of expanding the inclusion criteria where RCT evidence is lacking could be commendable and more representative of routine practice. Using the MMAT, the quality of reviewed and included studies in this systematic review was good overall.

Articles for inclusion were unfortunately limited to publications in the English language. There was an absence of studies on IUDs currently available in the UK and solely involving women aged under 30. This warranted including all ages if women under 30 years were involved, and up to (≤) 30 years for the TCu 380A data and meta-analysis because of the ages of the Hall and Kutler study participants (18–30 years). Many studies did not report all the required information, hence some included studies had missing information (table 3). Most studies did not differentiate between nulligravid and nulliparous participants, many age ranges were not specific (eg, ≤19–≥35), while some reports, for example, Sivin and Stern,[46] were a combination of individual studies. Similarly, it appeared common for older studies to only state numbers (rather than rates or percentages), or only graphically depict data on continuation rates or unwanted effects. It is also not unusual for a systematic review to include such studies, for example, Hubacher[7], and to calculate or measure rates accordingly, as has been done in this review. These are potential limitations which are not considered to impact the validity of the review. All mitigating actions that were taken have also been appropriately stated.

Relevance of findings

IUD use in young nulliparous women has been established to be safe, effective and acceptable.[52–54] It is recommended that women are provided with the most appropriate IUD types for their uterine cavity size. Uterine cavity width (measurable using a cavimeter or ultrasonography, not routinely practised) in addition to uterine length (routinely measured using a hysterome) should be recognised as influencing IUD type choice.[29 55–57] This systematic review suggests which IUD types may be more suitable for younger aged nulliparous women and emphasises the need for further research.

Recommendations

Strengthening the evidence for contraceptive choice and continuation is needed to improve sexual health in younger aged women. Prospective observational studies that include various IUD designs and types, and detailed reporting of users' experiences could facilitate a better understanding of early IUD discontinuation and reasons for discontinuation based on IUD types. Studies designed to overcome the challenges of recruiting large numbers from varied demographic backgrounds, significant loss to follow-up, and time or funding constraints are also likely to yield data widely applicable to IUC provision in and outside the UK.

CONCLUSION

Research is lacking on outcomes with the IUD types currently in use by young nulliparous women in the UK. Available evidence estimates a continuation rate of 81% at 12 months for the recommended standard-sized TCu 380A IUD in these women. More studies are needed to better estimate continuation rates for smaller sized and flexible IUDs in this user group.

Twitter Alison James @midwifeAliJ

Acknowledgements The authors are immensely grateful to the following for their expertise and support that greatly assisted this research: Diana Mansour, Consultant Community Gynaecologist, Newcastle upon Tyne Hospitals NHS Foundation Trust; Jill Shawe, Professor of Women's Health, University of Plymouth; Judith Stephenson, Margaret Pyke Professor of Sexual & Reproductive Health, University College London; Mark Chambers, Electronic Services Librarian, Newcastle upon Tyne Hospitals NHS Foundation Trust; and Nataliya Brima, PhD Fellow, Kings College London.

Contributors HA: Research idea, study design, protocol, searches, first reviewer, data summary, writing—original draft, review and editing, funding application for open access publishing, project administration and guarantor. AJ: Second reviewer, supervision, writing—review and editing, project administration. PB: Searches,

writing—review and editing. MM: Meta-analysis, writing—original draft, review and editing. JR: Contributed to research idea, study design, protocol, funding applications, and project administration, as well as supervision and writing—review and editing. All authors approved the final version.

Funding This work was supported by the British Medical Association's Foundation for Medical Research in the form of a Lift into Research 2019 grant to HA. JR is part-funded by the National Insitute of Health Research (NIHR) Applied Research Collaboration North East and North Cumbria, funded by the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) North East and North Cumbria (NIHR200173). The views expressed are those of the author(s) and not necessarily those of the British Medical Association's Foundation for Medical Research nor NIHR ARC.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

ORCID iDs
Hannat Akintomide http://orcid.org/0000-0002-7078-5697
Alison James http://orcid.org/0000-0001-5160-6684
Malcolm Moffat http://orcid.org/0000-0001-8808-2626

REFERENCES

1 Department of Health & Social Care: National Statistics. Abortion statistics, England and Wales: 2020, 2021. Available: https://www.gov.uk/government/statistics/abortion-statistics-for-england-and-wales-2020 [Accessed 20 Dec 2021].
2 NHS Digital. Statistics on sexual and reproductive health services (contraception): data (tables 6 and 7), 2021. Available: https://digital.nhs.uk/data-and-information/publications/statistical/sexual-and-reproductive-health-services/2020-21/data-tables [Accessed 23 Dec 2021].
3 BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National formulary, 2021. Available: https://bnf.nice.org.uk/medicinal-forms/intra-uterine-contraceptive-devices-copper.html [Accessed 20 Dec 2021].
4 Teal SB, Sheeder J. IUD use in adolescent mothers: retention, failure and reasons for discontinuation. *Contraception* 2012;85:270–4.
5 Akintomide H, Brima N, Mansour DJ, *et al*. Copper IUD continuation, unwanted effects and cost consequences at 1 year in users aged under 30 - a secondary analysis of the EURAS-IUD study. *Eur J Contracept Reprod Health Care* 2021;26:175–83.
6 Bateson D, Harvey C, Trinh L, *et al*. User characteristics, experiences and continuation rates of copper intrauterine device use in a cohort of Australian women. *Aust N Z J Obstet Gynaecol* 2016;56:655–61.
7 Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. *Contraception* 2007;75:S8–11.
8 Aoun J, Dines VA, Stovall DW, *et al*. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. *Obstet Gynecol* 2014;123:585–92.
9 O'Brien PA, Kulier R, Helmerhorst FM, *et al*. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. *Contraception* 2008;77:318–27.
10 National Institute for Health and Care Excellence. Long-acting reversible contraception: clinical guideline, 2015. Available: https://www.nice.org.uk/guidance/cg30 [Accessed 20 Dec 2021].
11 Clinical Effectiveness Unit. FSRH clinical guideline: intrauterine contraception, 2015 (Amended September 2019). Available: https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/ [Accessed 20 Dec 2021].
12 Akintomide H, Barnes P, Brima N, *et al*. Copper intrauterine contraception discontinuation in nulliparous and young women (CRD42019120969), 2019. PROSPERO - International prospective register of systematic reviews. Available: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019120969 [Accessed 25 Aug 2022].
13 Hong QN, Pluye P, Fabregues S, *et al*. Mixed methods appraisal tool (MMAT), version 2018, 2018. Available: http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf [Accessed 20 Dec 2021].
14 Borges Migliavaca C, Stein C, Colpani V, *et al*. How are systematic reviews of prevalence conducted? A methodological study. *BMC Med Res Methodol* 2020;20:96.
15 Higgins JPT, Thomas J, Chandler J, *et al*, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. version 6.3, 2022. www.training.cochrane.org/handbook
16 Rücker G, Schwarzer G, Carpenter JR, *et al*. Undue reliance on I(2) in assessing heterogeneity may mislead. *BMC Med Res Methodol* 2008;8:79.
17 Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16:195–203.
18 The Contraception Priority Setting Partnership. The 'Top 10' unanswered research priorities for contraceptive care, in The Contraception Priority Setting Partnership Report; 2018. https://www.fsrh.org/documents/fsrh-contraception-psp-report-2018-jla/ [Accessed 25 Aug 2022].
19 Abraham M, Zhao Q, Peipert JF. Young age, Nulliparity, and continuation of long-acting reversible contraceptive methods. *Obstet Gynecol* 2015;126:823–9.
20 Garbers S, Haines-Stephan J, Lipton Y, *et al*. Continuation of copper-containing intrauterine devices at 6 months. *Contraception* 2013;87:101–6.
21 Goldstuck ND. Clinical evaluation of the combined multiload copper 250-mini IUD in selected nulliparous women. *Contracept Deliv Syst* 1980;1:379–87.
22 Lete I, Morales P, de Pablo JL. Use of intrauterine contraceptive devices in nulliparous women: personal experience over a 12-year period. *Eur J Contracept Reprod Health Care* 1998;3:190–3.
23 Ogedengbe OK, Giwa-Osagie OF, Oye-Adeniran BA. A comparison of multiload with Copper-T IUDs in a family planning clinic in Lagos. *Br J Fam Plann* 1991;17:67–9.
24 Phillips SJ, Hofler LG, Modest AM, *et al*. Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study. *Am J Obstet Gynecol* 2017;217:57.e1–57.e6.
25 Sivin I, Tatum HJ. Four years of experience with the TCu 380A intrauterine contraceptive device. *Fertil Steril* 1981;36:159–63.
26 Teal SB, Romer SE, Goldthwaite LM, *et al*. Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. *Am J Obstet Gynecol* 2015;213:515.e1–515.e5.
27 Hindle WH. Clinical evaluation and follow-up on 3,829 IUD procedures. *Trans Pac Coast Obstet Gynecol Soc* 1978;45:105–10.
28 Patnaik BP, Mishra KP. User satisfaction and retention of Cu-T (IUD) amongst rural women in Orissa. *Health and Population: Perspectives and Issues* 2003;26:52–8.
29 Petersen KR, Brooks L, Jacobsen N, *et al*. Clinical performance of intrauterine devices in nulligravidae: is the length of the endometrial cavity of significance? *Acta Eur Fertil* 1991;22:225–8.
30 Akintomide H, Barnes P, Brima N, *et al*. Higher discontinuation rate with a standard-sized compared to a small-sized 'gold standard' copper intrauterine device: a case-control review. *BMJ Sex Reprod Health* 2019;45:263–8.
31 Allonen H, Luukkainen T, Nielsen NC, *et al*. Two-year rates for nova T and copper T in a comparative study. *Contraception* 1980;21:321–34.
32 Elkhateeb RR, Kishk E, Sanad A, *et al*. The acceptability of using IUDs among Egyptian nulliparous women: a cross-sectional study. *BMC Womens Health* 2020;20:1–6.

33 Fugere P. Five years experience of intrauterine contraception with the Nova-T. *Contraception* 1990;41:1–7.
34 Hall AM, Kutler BA. Intrauterine contraception in nulliparous women: a prospective survey. *J Fam Plann Reprod Health Care* 2016;42:36–42.
35 Kaislasuo J, Heikinheimo O, Lähteenmäki P, *et al*. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception. *Hum Reprod* 2015;30:1580–8.
36 Larsen S, Hansen MK, Jacobsen JC, *et al*. Comparison between two IUDs: Progestasert and cut 200. *Contracept Deliv Syst* 1981;2:281–6.
37 Lewit S. Two years of experience with the Copper-T: a research report. *Stud Fam Plann* 1973;4:171–2.
38 Liedholm P, Sjöberg NO. Two years experience with copper-T 200 in a Swedish population-a comparison between nulliparous and parous women. *Contraception* 1974;10:55–61.
39 Luukkainen T, Nielsen N-C, Nygren K-G, *et al*. Randomized comparison of clinical performance of two copper-releasing IUDs, Nova-T and Copper-T-200, in Denmark, Finland and Sweden. *Contraception* 1979;19:1–9.
40 Luukkainen T, Allonen H, Haukkamaa M, *et al*. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. *Contraception* 1987;36:169–79.
41 Mishell DR, Israel R, Freid N. A study of the copper T intrauterine contraceptive device (TCu 200) in nulliparous women. *Am J Obstet Gynecol* 1973;116:1092–6.
42 Nygren KG, Nielsen NC, Pyörälä T, *et al*. Intrauterine contraception with Nova-T and copper-T-200 during three years. *Contraception* 1981;24:529–42.
43 Ostergard DR, Gunning JE. Intrauterine contraception with the copper T-200 and the Dalkon shield in nulligravid women. *J Reprod Med* 1976;17:172–4.
44 Otero-Flores JB, Guerrero-Carreño FJ, Vázquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. *Contraception* 2003;67:273–6.
45 Roy S, Cooper D, Mishell DR. Experience with three different models of the copper T intrauterine contraceptive device in nulliparous women. *Am J Obstet Gynecol* 1974;119:414–7.
46 Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 1970-75. *Stud Fam Plann* 1979;10:263–81.
47 Timonen H, Toivonen J, Luukkainen T. Use-effectiveness of the copper-T300 during the first year. *Am J Obstet Gynecol* 1974;120:466–9.
48 Page M, McKenzie J, Bossuyt P, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J* 2021;372.
49 Inoue K, Barratt A, Richters J. Does research into contraceptive method discontinuation address women's own reasons? A critical review. *J Fam Plann Reprod Health Care* 2015;41:292–9.
50 Museum of New Zealand. IUD 'Copper-T200, Schering'. Object | Part of History Collection. Available: https://collections.tepapa.govt.nz/object/1340909 [Accessed 23 Dec 2021].
51 O'Brien P. The effects of increasing the copper load on IUD performance: a systematic review. *Eur J Contracept Reprod Health Care* 2004;9:93.
52 Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. *Contraception* 2017;95:17–39.
53 Foran T, Butcher BE, Kovacs G, *et al*. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review. *Eur J Contracept Reprod Health Care* 2018;23:379–86.
54 Bahamondes MV, Bahamondes L. Intrauterine device use is safe among nulligravidas and adolescent girls. *Acta Obstet Gynecol Scand* 2021;100:641–8.
55 Kurz KH, Tadesse E, Haspels AA. In vivo measurements of uterine cavities in 795 women of fertile age. *Contraception* 1984;29:495–510.
56 Bahamondes MV, Monteiro I, Canteiro R, *et al*. Length of the endometrial cavity and intrauterine contraceptive device expulsion. *Int J Gynaecol Obstet* 2011;113:50–3.
57 Wildemeersch D, Hasskamp T, Nolte K, *et al*. A multicenter study assessing uterine cavity width in over 400 nulliparous women seeking IUD insertion using 2D and 3D sonography. *Eur J Obstet Gynecol Reprod Biol* 2016;206:232–8.

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1 Supplemental material 1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pages 1-2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pages 2-3
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 2 Supplemental material 3
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 2 Supplemental material 3
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pages 2-3
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pages 2-3
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 3
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 3
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pages 2-3 Supplemental material 6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 3
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 3
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 3
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page 3
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-	Page 3

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
		regression).	
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 3 Supplemental material 4
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page 3
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 3
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 5 Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 5 Supplemental material 5
Study characteristics	17	Cite each included study and present its characteristics.	Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table 2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Pages 5-11 Tables 3-4 Figures 2–7 Supplemental material 9
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplemental material 4,7,8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pages 7-11 Table 4 Figures 2–7
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Pages 7-11 Table 4 Figures 2–7 Supplemental material 7,8
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary material 4
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Pages 7-11 Table 4 Figures 2–7 Supplemental material 4,7,8
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Pages 7-11 Table 4

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
			Figures 2–7 Supplemental material 4,7,8
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pages 11-12
	23b	Discuss any limitations of the evidence included in the review.	Page 12
	23c	Discuss any limitations of the review processes used.	Page 12
	23d	Discuss implications of the results for practice, policy, and future research.	Page 12
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 2 Supplemental material 2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 2 Supplemental material 2
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Pages 2 and 5
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 13
Competing interests	26	Declare any competing interests of review authors.	Page 13
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Not applicable

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

PROSPERO
International prospective register of systematic reviews

NHS National Institute for Health Research

Copper intrauterine contraception discontinuation in nulliparous and young women

Hannat Akintomide, Pam Barnes, Nataliya Brima, Judith Rankin

Citation

Hannat Akintomide, Pam Barnes, Nataliya Brima, Judith Rankin. Copper intrauterine contraception discontinuation in nulliparous and young women. PROSPERO 2019 CRD42019120969 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019120969

Review question

Which copper intrauterine devices are associated with higher discontinuation rates in young and nulliparous women?

Searches

Databases [including the Cochrane Library, the Database of Abstracts and Reviews of Effects (DARE), MEDLINE (Ovid), Excerpta Medica Database (EMBASE), Turning Research into Practice (TRIP) database and National Electronic Library of Health] and relevant websites [including Bandolier, Medicines and Healthcare products Regulatory Agency, Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists, Department of Health, Medical Defence Unions, National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines, World Health Organisation and Google Scholar] will be searched using MeSH terms combined with key words for relevant articles published from 1966 to date. Reference lists of relevant articles will also be searched to identify more articles. The full texts of relevant articles will be screened, duplicates excluded and then data from selected articles included in the review.

Randomised controlled trials (RCTs) involving copper intrauterine devices (IUDs) available or comparable to those in the UK published in English will be included. Other studies that report on the main outcome (observational and qualitative studies) will be included and/or summarised if the number of RCTs eligible for inclusion are too few to answer the review question.

Key words

Copper intrauterine device related: copper intrauterine device, copper intrauterine contraceptive device, copper intrauterine contraception, copper coil, IUD

Nulliparous related: nulliparous, nulligravid, never pregnant, never delivered

Young women related: young women, adolescent, aged under, teenage

Types of study to be included

Inclusion criteria: Articles published in English on studies in women who are nulliparous and aged under 30 that involved copper intrauterine devices available, or of the same design and size to those available, in the UK.

Exclusion criteria: Articles not published in English, studies solely in parous women aged 30 or over, or that involved copper intrauterine devices not available, or not of the same design and size to those available, in the UK.

Condition or domain being studied

Copper intrauterine contraception in nulliparous and young women

Participants/population

Women who are nulliparous and aged under 30

Intervention(s), exposure(s)

Copper intrauterine devices available or comparable to those in the UK

Comparator(s)/control

Any IUD, other contraceptive or no contraception where applicable

PROSPERO
International prospective register of systematic reviews

NHS National Institute for Health Research

Context
Copper intrauterine devices (IUDs) are of various shapes, sizes, copper surface area and copper distribution on the frame of the device. There are many types of IUDs available in the UK but none shown to be associated with better outcomes in nulliparous and young women. The identification and use of those IUDs associated with less discontinuation could improve outcomes including satisfaction and continuation rates of intrauterine contraception in nulliparous and younger women.

Main outcome(s)
Copper intrauterine contraception discontinuation rates in nulliparous and young women based on type of IUD

Timing and effect measures

Additional outcome(s)
Reasons for IUD discontinuation

Timing and effect measures

Data extraction (selection and coding)
The abstracts of published articles obtained from the literature and websites searches will be reviewed by two authors to assess eligibility for inclusion in the systematic review based on the inclusion/exclusion criteria. All retrieved full texts of published articles will be reviewed to agree which studies to include in the systematic review, with disagreements resolved by the third author. All retrieved articles to be included in the systematic review will undergo a quality assessment using a risk of bias tool applicable to the type of study.

Main data to be extracted:

type of copper intrauterine device (IUD)

age of women

gravidity/parity of women

place/time of IUD insertion

IUD discontinuation rate(s)

reason(s) for IUD discontinuation

Risk of bias (quality) assessment
All retrieved articles to be included in the systematic review will undergo a quality assessment. One author will complete the inclusion criteria checklist while the second author will review the checklist, with disagreements resolved by the third author/consensus. Retrieved articles with a high risk of bias will be excluded from the systematic review.

Strategy for data synthesis
Data from the included studies will be extracted using a standardised form by one author while the second author will check these. Disagreements will be resolved by a further review of the study with the third author and consensus. One author will enter the extracted data into Review Manager (RevMan®) Software while the second author will again check these for accuracy. It is planned that aggregate data will be used. However, individual data on the intervention and population of interest (IUDs in nulliparous and young women aged under 30) will be extracted where studies have reported on this subgroup their outcomes in conjunction with other population subgroups or study outcomes.
A quantitative synthesis is planned based on the expected homogeneity of the data to be obtained for the main outcome to be studied. This homogeneous data will be combined for meta-analysis. Heterogeneous

PROSPERO
International prospective register of systematic reviews

NHS National Institute for Health Research

data, some of which is expected to be obtained on the additional outcome, will be narratively synthesised.

Analysis of subgroups or subsets
IUDs of same size and design will be grouped and discontinuation rates presented based on IUD type.

Contact details for further information
Hannat Akintomide
h.akintomide@nhs.net

Organisational affiliation of the review
Newcastle upon Tyne Hospitals NHS Foundation Trust
King's College London
Newcastle University

Review team members and their organisational affiliations
Dr Hannat Akintomide. Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Pam Barnes. Newcastle upon Tyne Hospitals NHS Foundation Trust
Mrs Nataliya Brima. King's College London
Professor Judith Rankin. Newcastle University

Anticipated or actual start date
28 January 2019

Anticipated completion date
31 January 2020

Funding sources/sponsors
Nil

Conflicts of interest

Language
English

Country
England

Stage of review
Review_Ongoing

Subject index terms status
Subject indexing assigned by CRD

Subject index terms
Contraception; Copper; Female; Humans; Intrauterine Devices; Parity; Pregnancy

Date of registration in PROSPERO
07 February 2019

Date of publication of this version
07 February 2019

Details of any existing review of the same topic by the same authors

Stage of review at time of this submission

PROSPERO
International prospective register of systematic reviews

NHS National Institute for Health Research

Stage	Started	Completed
Preliminary searches	Yes	No
Piloting of the study selection process	Yes	No
Formal screening of search results against eligibility criteria	No	No
Data extraction	No	No
Risk of bias (quality) assessment	No	No
Data analysis	No	No

Versions

07 February 2019

Table – Search Strategies

Databases and additional sources search	Search term(s) used	Limits	Records identified
Allied and Complementary Medicine (AMED) British Nursing Index (BNI) Cumulative Index to Nursing and Allied Health Literature (CINAHL) Excerpta Medica Database (EMBASE) Nursing and Allied Health Professionals Database (EMCARE) Health Management Information Consortium (HMIC) General Medical Database (MEDLINE) Psychology and Allied Fields (PsychINFO) PubMed	(copper intrauterine).ti,ab OR (copper intrauterine device).ti,ab OR (copper coil).ti,ab OR (copper IUD).ti,ab OR (copper T).ti,ab	Title, Abstract English language	**725**
The Cochrane Library Database of Abstracts and Reviews of Effects (DARE) Turning Research into Practice (TRIP) Bandolier National Electronic Library of Health Medicines and Healthcare products Regulatory Agency (MHRA) Faculty of Sexual and Reproductive Healthcare (FSRH) Royal College of Obstetricians and Gynaecologists (RCOG) Department of Health National Institute for Health and Care Excellence (NICE) Scottish Intercollegiate Guidelines, World Health Organisation (WHO)	'copper intrauterine'	-	**22**
Google Scholar	'copper intrauterine device young nulliparous'	-	

TCu 380A continuation at 12 months post-insertion – sensitivity analysis

Subgroup 1 (Nulliparous women aged <30 years)	**(81.60% (95% CI 76.52-86.21%))**
Excluding Abraham et al. (<20)	82.04% (95% CI 76.48-87.04%)
Excluding Abraham et al. (20-25)	78.01% (95% CI 66.60-87.74%)
Excluding Hall and Kutler (18-30)	81.83% (95% CI 76.66-86.49%)
Subgroup 2 (Nulliparous women of any age)	**(80.97% (95% CI 76.04-85.48%))**
Excluding Abraham et al. (>25)	81.99% (95% CI 79.19-84.63%)
Excluding Akintomide et al. (15-37)	81.94% (95% CI 79.41-84.34%)
Excluding Roy et al. (14-33)	80.12% (95% CI 73.92-85.70%)
Overall effect size (all studies)	**(81.93% (95% CI 79.66-84.09%))**
Excluding Abraham et al. (<20)	81.84% (95% CI 79.13-84.40%)
Excluding Abraham et al. (20-25)	81.44% (95% CI 78.16-84.53%)
Excluding Hall and Kutler (18-30)	81.87% (95% CI 79.60-84.03%)
Excluding Abraham et al. (>25)	81.57% (95% CI 78.38-84.58%)
Excluding Akintomide et al. (15-37)	82.14% (95% CI 79.87-84.31%)
Excluding Roy et al. (14-33)	80.92% (95% CI 76.93-84.64%)

TCu 200 continuation at 12 months post-insertion – sensitivity analysis

Subgroup 1 (Nulliparous women aged <30 years)	**(73.03% (95% CI 67.63-78.10%))**
Excluding Lewit (15-19)	75.26% (95% CI 73.90-76.59%)
Excluding Lewit (20-24)	73.33% (95% CI 71.62-75.00%)
Excluding Lewit (25-29)	71.78% (95% CI 70.30-73.24%)
Subgroup 2 (Nulliparous women of any age)	**(76.51% (95% CI 72.67-80.14%))**
Excluding Roy et al. (14-33)	76.83% (95% CI 72.49-80.91%)
Excluding Luukkainen et al. (19-35)	76.53% (95% CI 71.86-80.91%)
Excluding Larsen et al. (15-44)	76.85% (95% CI 72.79-80.67%)
Excluding Ostergard and Gunning (18-34)	76.84% (95% CI 72.76-80.69%)
Excluding Lewit (30-34)	75.59% (95% CI 71.42-79.54%)
Excluding Lewit (35-49)	75.20% (95% CI 71.98-78.29%)
Excluding Liedholm and Sioberg (14-40)	77.32% (95% CI 73.40-81.01%)
Excluding Mishell et al. (14-33)	76.84% (95% CI 72.51-80.91%)
Overall effect size (all studies)	**(75.44% (95% CI 72.32-78.43%))**
Excluding Lewit (15-19)	76.43% (95% CI 73.71-79.04%)
Excluding Lewit (20-24)	75.59% (95% CI 71.81-79.17%)
Excluding Lewit (25-29)	76.16% (95% CI 71-60-78.56%)
Excluding Roy et al. (14-33)	75.56% (95% CI 72.16-78.81%)
Excluding Luukkainen et al. (19-35)	75.38% (95% CI 71.89-78.72%)
Excluding Larsen et al. (15-44)	75.60% (95% CI 72.34-78.70%)
Excluding Ostergard and Gunning (18-34)	75.59% (95% CI 72.33-78.71%)
Excluding Lewit (30-34)	74.72% (95% CI 71.59-77.73%)

Akintomide H, *et al. BMJ Open* 2022; 12:e060606. doi: 10.1136/bmjopen-2021-060606

Excluding Lewit (35-49)	74.37% (95% CI 71.53-77.10%)
Excluding Liedholm and Sioberg (14-40)	75.87% (95% CI 72.61-78.98%)
Excluding Mishell et al. (14-33)	75.56% (95% CI 72.16-78.81%)

TCu 200 discontinuation at 12 months due to pain/bleeding – sensitivity analysis

Subgroup 1 (Nulliparous women aged <30 years)	**(7.05% (95% CI 5.59-8.65%))**
Excluding Lewit (15-19)	7.31% (95% CI 6.52-8.14%)
Excluding Lewit (20-24)	6.31% (95% CI 5.41-7.27%)
Excluding Lewit (25-29)	7.88% (95% CI 7.02-8.78%)
Subgroup 2 (Nulliparous women of any age)	**(12.77% (95% CI 8.48-17.78%))**
Excluding Roy et al. (14-33)	13.10% (95% CI 8.10-19.06%)
Excluding Luukkainen et al. (19-35)	11.02% (95% CI 8.41-13.92%)
Excluding Larsen et al. (15-44)	12.40% (95% CI 7.87-17.76%)
Excluding Ostergard and Gunning (18-34)	12.86% (95% CI 8.20-18.35%)
Excluding Lewit (30-34)	13.61% (95% CI 8.83-19.22%)
Excluding Lewit (35-49)	13.79% (95% CI 9.10-19.25%)
Excluding Liedholm and Sioberg (14-40)	12.08% (95% CI 7.56-17.45%)
Excluding Mishell et al. (14-33)	13.13% (95% CI 8.13-19.08%)
Overall effect size (all studies)	**(10.87% (95% CI 7.98-14.15%))**
Excluding Lewit (15-19)	11.37% (95% CI 8.08-15.12%)
Excluding Lewit (20-24)	11.23% (95% CI 7.70-15.32%)
Excluding Lewit (25-29)	11.52% (95% CI 8.34-15.14%)
Excluding Roy et al. (14-33)	10.90% (95% CI 7.77-14.47%)
Excluding Luukkainen et al. (19-35)	9.32% (95% CI 7.62-11.17%)
Excluding Larsen et al. (15-44)	10.51% (95% CI 7.58-13.86%)
Excluding Ostergard and Gunning (18-34)	10.78% (95% CI 7.77-14.20%)
Excluding Lewit (30-34)	11.23% (95% CI 8.01-14.92%)
Excluding Lewit (35-49)	11.34% (95% CI 8.17-14.94%)
Excluding Liedholm and Sioberg (14-40)	10.26% (95% CI 7.40-13.53%)
Excluding Mishell et al. (14-33)	10.92% (95% CI 7.78-14.50%)

TCu 200 discontinuation at 12 months due to expulsion – sensitivity analysis

Subgroup 1 (Nulliparous women aged <30 years)	**(10.52% (95% CI 7.17-14.41%))**
Excluding Lewit (15-19)	8.59% (95% CI 7.74-9.48%)
Excluding Lewit (20-24)	11.21% (95% CI 10.03-12.44%)
Excluding Lewit (25-29)	10.36% (95% CI 9.38-11.38%)
Subgroup 2 (Nulliparous women of any age)	**(4.93% (95% CI 2.93-7.39%))**
Excluding Roy et al. (14-33)	4.85% (95% CI 2.57-7.78%)
Excluding Luukkainen et al. (19-35)	4.17% (95% CI 2.68-5.96%)
Excluding Larsen et al. (15-44)	4.92% (95% CI 2.79-7.58%)
Excluding Ostergard and Gunning (18-34)	4.80% (95% CI 2.69-7.46%)
Excluding Lewit (30-34)	4.74% (95% CI 2.41-7.76%)
Excluding Lewit (35-49)	5.24% (95% CI 3.03-7.99%)
Excluding Liedholm and Sioberg (14-40)	5.84% (95% CI 3.95-8.07%)

Excluding Mishell et al. (14-33)	4.85% (95% CI 2.57-7.77%)
Overall effect size (all studies)	**(6.44% (95% CI 4.49-8.69%))**
Excluding Lewit (15-19)	5.76% (95% CI 4.14-7.61%)
Excluding Lewit (20-24)	6.16% (95% CI 3.87-8.93%)
Excluding Lewit (25-29)	6.16% (95% CI 3.96-8.79%)
Excluding Roy et al. (14-33)	6.55% (95% CI 4.47-8.99%)
Excluding Luukkainen et al. (19-35)	6.01% (95% CI 3.98-8.42%)
Excluding Larsen et al. (15-44)	6.54% (95% CI 4.51-8.91%)
Excluding Ostergard and Gunning (18-34)	6.46% (95% CI 4.43-8.83%)
Excluding Lewit (30-34)	6.47% (95% CI 4.36-8.95%)
Excluding Lewit (35-49)	6.87% (95% CI 4.87-9.18%)
Excluding Liedholm and Sioberg (14-40)	7.29% (95% CI 5.39-9.45%)
Excluding Mishell et al. (14-33)	6.55% (95% CI 4.47-8.99%)

TCu 200 discontinuation at 12 months due to pregnancy – sensitivity analysis

Subgroup 1 (Nulliparous women aged <30 years)	**(2.19% (95% CI 1.47-3.05%))**
Excluding Lewit (15-19)	2.27% (95% CI 1.82-2.75%)
Excluding Lewit (20-24)	1.83% (95% CI 1.35-2.39%)
Excluding Lewit (25-29)	2.63% (95% CI 2.13-3.18%)
Subgroup 2 (Nulliparous women of any age)	**(1.15% (95% CI 0.54-1.95%))**
Excluding Roy et al. (14-33)	1.07% (95% CI 0.40-1.99%)
Excluding Luukkainen et al. (19-35)	0.96% (95% CI 0.38-1.75%)
Excluding Larsen et al. (15-44)	1.18% (95% CI 0.53-2.05%)
Excluding Ostergard and Gunning (18-34)	1.31% (95% CI 0.65-2.16%)
Excluding Lewit (30-34)	1.35% (95% CI 0.70-2.18%)
Excluding Lewit (35-49)	1.31% (95% CI 0.62-2.20%)
Excluding Liedholm and Sioberg (14-40)	1.00% (95% CI 0.42-1.78%)
Excluding Mishell et al. (14-33)	1.07% (95% CI 0.40-1.99%)
Overall effect size (all studies)	**(1.49% (95% CI 0.96-2.13%))**
Excluding Lewit (15-19)	1.39% (95% CI 0.81-2.09%)
Excluding Lewit (20-24)	1.34% (95% CI 0.83-1.94%)
Excluding Lewit (25-29)	1.48% (95% CI 0.87-2.22%)
Excluding Roy et al. (14-33)	1.46% (95% CI 0.89-2.16%)
Excluding Luukkainen et al. (19-35)	1.40% (95% CI 0.83-2.09%)
Excluding Larsen et al. (15-44)	1.53% (95% CI 0.98-2.19%)
Excluding Ostergard and Gunning (18-34)	1.62% (95% CI 1.07-2.26%)
Excluding Lewit (30-34)	1.69% (95% CI 1.18-2.29%)
Excluding Lewit (35-49)	1.64% (95% CI 1.10-2.28%)
Excluding Liedholm and Sioberg (14-40)	1.41% (95% CI 0.88-2.06%)
Excluding Mishell et al. (14-33)	1.46% (95% CI 0.89-2.16%)

Table – Characteristics of studies excluded following full text assessment

Study / Authors	Year	Country	Study Design	Study Objectives	Reasons for Exclusion
Akintomide et al[5]	2021	Austria, Finland, Germany, Poland, Sweden, UK	Prospective cohort	Secondary analysis of continuation, unwanted effects and cost consequences at 1 year in IUD users ≤30 in the European Active Surveillance Study for Intrauterine Devices	Undifferentiable results - IUD type categories based on IUD characteristics rather than brand or name of IUD
Garbers et al[20]	2013	USA	Retrospective records review	Prevalence and predictors of IUD discontinuation at 6 months in 306 Cu T380A users	Undifferentiable results; varied duration; 23 excluded from continuation analysis
Goldstuck[21]	1980	UK	Prospective cohort (selected)	Clinical evaluation of the combined multiload copper 250-mini IUD in selected nulliparous women	Undifferentiable results; disparity between data in tables and text
Hindle[27]	1978	Unable to confirm		Clinical evaluation and follow-up on 3,829 IUD procedures	Full text unobtainable
Lete et al[22]	1998	Spain	Prospective cross-sectional	Evaluation of IUD use in nulliparous women compared to parous women over a 12-year period	Data reported as incidence of events rather than rates
Ogedengbe et al[23]	1991	Nigeria	Prospective cohort	A comparison efficacy and discontinuation at 1 year of multiload and copper-T IUDs sequentially assigned to users	Parity of participants not detailed (mean parity 4); only one nulliparous participant
Patnaik[28]	2003	India	Unable to confirm	Uptake, satisfaction, retention and reasons for discontinuation of the copper T IUD	Full text unobtainable
Petersen et al[29]	1991	Unable to confirm	RCT – double blind	Significance of endometrial cavity length in the clinical performance of IUDs in nulligravidae	Full text unobtainable
Phillips et al[24]	2017	USA	Retrospective records review	Comparison of continuation and performance of levonorgestrel and copper intrauterine devices over 5 years	Undifferentiable results
Sivin and Tatum[25]	1981	USA	Prospective cohort	Clinical performance of the TCu 380A IUD over 4 years	Undifferentiable results
Teal et al[26]	2015	USA	Retrospective records review	Evaluation of the success and safety of intrauterine device (IUD) placement in adolescents based on age and parity	Undifferentiable results

References

5. Akintomide H, Brima N, Mansour DJ, et al, Copper IUD continuation, unwanted effects and cost consequences at 1 year in users aged under 30 – a secondary analysis of the EURAS-IUD study. The European Journal of Contraception & Reproductive Health Care, 2021. 26(3): p. 175-183.

20. Garbers S, Haines-Stephan J, Lipton Y, et al, Continuation of copper-containing intrauterine devices at 6 months. Contraception, 2013. 87(1): p. 101-106.

21. Goldstuck ND, Clinical evaluation of the combined multiload copper 250-mini IUD in selected nulliparous women. Contraceptive delivery systems, 1980. 1(4): p. 379-387.

27. Hindle WH, Clinical evaluation and follow-up on 3,829 IUD procedures. Transactions of the Pacific Coast Obstetrical and Gynecological Society, 1978. 45: p. 105-110.

22. Lete I, Morales P and De Pablo JL, Use of intrauterine contraceptive devices in nulliparous women: personal experience over a 12-year period. The European Journal of Contraception & Reproductive Health Care, 1998. 3(4): p. 190-193.

23. Ogedengbe OK, Giwa-Osagie OF and Oye-Adeniran BA, A comparison of multiload with Copper-T IUDs in a family planning clinic in Lagos. British Journal of Family Planning, 1991. 17(3): p. 67-69.

28. Patnaik BP and Mishra KP, User satisfaction and retention of Cu-T (IUD) amongst rural women in Orissa. Health and Population: Perspectives and Issues, 2003. 26(2): p. 52-58.

29. Petersen KR, Brooks L Fau - Jacobsen N, Jacobsen N Fau - Skoby SO, et al, Clinical performance of intrauterine devices in nulligravidae: is the length of the endometrial cavity of significance? Acta Eur Fertil, 1991. 22(4): p. 225-8.

24. Phillips SJ, Hofler LG, Modest AM, et al, Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study. American journal of obstetrics and gynecology, 2017. 217(1): p. 57.e1-57.e6.

25. Sivin I and Tatum HJ, Four years of experience with the TCu 380A intrauterine contraceptive device. Fertility and sterility, 1981. 36(2): p. 159-163.

26. Teal SB, Romer SE, Goldthwaite LM, et al. Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. *Am J Obstet Gynecol* 2015;213(4):515.e1-5. doi: 10.1016/j.ajog.2015.06.

Table – Quality Assessment of Included Studies Using the Mixed Methods Appraisal Tool (MMAT) version 2018

Study / Authors	*Design Category*	*Responses to MMAT Questions (and Scores): Yes (1) / No (0) / Can't Tell (0)*							
		Screening 1	**Screening 2**	**Appraisal 1**	**Appraisal 2**	**Appraisal 3**	**Appraisal 4**	**Appraisal 5**	**Total**
Abraham et al 2015	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Akintomide et al 2019	Quantitative, non-randomised	yes	yes	yes	yes	no	yes	yes	6
Allonen et al 1980	Quantitative, randomised	yes	yes	can't tell	yes	yes	yes	yes	6
Elkhateeb et al 2020	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Fugere 1990	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Hall and Kutler 2015	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Kaislasuo et al 2015	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Larsen et al 1981	Quantitative, randomised	yes	yes	can't tell	yes	yes	no	yes	5
Lewit 1973	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Liedholm and Sjoberg 1974	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Luukkainen et al 1979	Quantitative, randomised	yes	yes	can't tell	yes	yes	yes	yes	6
Luukkainen et al 1987	Quantitative, randomised	yes	yes	yes	yes	yes	no	yes	6
Mishell et al 1973	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Nygren et al 1981	Quantitative, randomised	yes	yes	yes	yes	yes	yes	yes	7
Ostergard and Gunning 1979	Quantitative, randomised	yes	yes	yes	can't tell	yes	no	yes	5
Otero-Flores et al 2003	Quantitative, randomised	yes	yes	yes	yes	yes	no	yes	6
Roy et al 1974	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7
Sivin and Stern 1979	Quantitative, randomised	yes	yes	can't tell	can't tell	yes	yes	yes	5
Timonen et al 1974	Quantitative, non-randomised	yes	yes	yes	yes	yes	yes	yes	7

Tau^2 Values for Heterogeneity of Included Studies

IUD type	Tau^2 Values for Heterogeneity of Included Studies for Continuation Rates		
	Nulliparous women aged <30	**Nulliparous women of any age**	**Overall effect size (all studies)**
TCu 380A excluding Otero- Flores data	0.0[a] [19, 34]	0.005 [19, 30, 45]	0.0 [19, 30, 34, 45]
TCu 380A including Otero- Flores data	0.487 [19, 34, 44]	0.005 [19, 30, 44, 45]	0.299 [19, 30, 34, 44, 45]
Smaller TCu 380A[b]	not applicable – only one study group	0.0 [30, 44]	0.0 [30, 44]
TCu 300	not applicable – no study	0.0 [45, 47]	0.0 [45, 47]
TCu 200	0.010 [37]	0.012 [37-39, 41, 43, 45]	0.012 [37-39, 41, 43, 45]
Nova T200	not applicable – no study	0.0 [39, 40]	0.0 [39, 40]
	Tau^2 Values for Heterogeneity of Included Studies for Discontinuation Rates		
TCu 200 discontinuation due to bleeding/pain	0.001 [37]	0.036 [36-39, 41, 43, 45]	0.025 [36-39, 41, 43, 45]
TCu 200 discontinuation due to expulsion	0.010 [37]	0.018 [36-39, 41, 43, 45]	0.018 [36-39, 41, 43, 45]
TCu 200 discontinuation due to pregnancy	0.002 [37]	0.005 [36-39, 41, 43, 45]	0.004 [36-39, 41, 43, 45]

a – includes women aged 30 from Hall and Kutler study data; b – TCu 380A Nul/Mini TT380 Slimline IUDs

Supplementary material – Doi plots



Figure 1 - Doi plot for TCu 380A continuation at 12 months



Figure 2 – Doi plot for TCu 200 continuation at 12 months

Supplementary material – Doi plots



Figure 3 – Doi plot for TCu 200 discontinuation at 12 months due to bleeding/pain



Figure 4 – Doi plot for TCu 200 discontinuation at 12 months due to expulsion

Supplementary material – Doi plots



Figure 5 – Doi plot for TCu 200 discontinuation due to pregnancy

Supplementary material – TCu 200 discontinuation rates due to pain/bleeding, expulsion and pregnancy



Figure 1 - TCu 200 discontinuation at 12 months due to pain/bleeding



Figure 2 – TCu 200 discontinuation at 12 months due to expulsion

Supplementary material – TCu 200 discontinuation rates due to pain/bleeding, expulsion and pregnancy



Figure 3 – TCu 200 discontinuation at 12 months due to pregnancy